洛铂与顺铂联合培美曲塞一线治疗晚期肺腺癌的临床观察  

Clinical Study of Pemetrexed plus Lobaplatin versus Pemetrexed plus Cisplatin as the First Line Treatment for Advanced Lung Adenocarcinoma

作　　者：董岩[1] 李颖[1] 高亚杰[1] 

机构地区：[1]大连医科大学附属第一医院肿瘤科,辽宁大连116011

出　　处：《医学与哲学（B）》2011年第10期27-28,49,共3页Medicine & Philosophy(B)

摘　　要：观察洛铂与顺铂联合培美曲塞治疗晚期肺腺癌的疗效和不良反应。将64例肺腺癌患者分为PL组(培美曲塞+洛铂)和PC组(培美曲塞+顺铂),每2个周期评价疗效,观察不良反应。结果两组疗效无显著差异。PL组恶心、呕吐、腹泻较轻,口腔黏膜炎反应较重。结论两组疗效相当,但洛铂组不良反应较轻,耐受性好。To observe the effectiveness and toxicities of Lobaplatin （LBP） or Cisplatin （DDP） combined with Pemetrexed for the treatment of advanced lung adenocarcinoma,64 lung cancer patients were randomly assigned into PL group （Pemetrexed ＋LBP） and PC group I Pemetrexed＋DDP）. The curative effects and adverse reactions were assessed every 2 cycles. The results showed there was no significant difference in curative effects between the two groups, and digestive toxicity in the PL group, such as nausea, vomiting, and diarrhea was lighter, but oral mucositis was more than that in the PC group. Therefore Lobaplatin with Pemetrexed provides similar efficacy to Cisplatin plus Pemetrexed for advanced lung adenocarcinoma, but is less toxicity and well tolerated

关 键 词：洛铂 培美曲塞 肺肿瘤 腺癌 联合化疗 

分 类 号：R734.2[医药卫生—肿瘤]